4.6 Article

Cortical Regulation of Striatal Medium Spiny Neuron Dendritic Remodeling in Parkinsonism: Modulation of Glutamate Release Reverses Dopamine Depletion-Induced Dendritic Spine Loss

期刊

CEREBRAL CORTEX
卷 20, 期 10, 页码 2423-2432

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cercor/bhp317

关键词

cortex; corticostriatal; dendritic remodeling; metabotropic glutamate receptors; mGluR2; 3; Parkinson's disease

资金

  1. National Institute of Neurological Disorders and Stroke (NINDS)
  2. National Institute of Mental Health (NIMH)
  3. National Institutes of Health [F31 NS060174, RO1 MH077298, PO1 NS44282]
  4. Eunice Kennedy Shriver National Institute of Child Health and Human Development [P30 HD15052]
  5. National Parkinson Foundation Center of Excellence at Vanderbilt

向作者/读者索取更多资源

Striatal medium spiny neurons (MSNs) receive glutamatergic afferents from the cerebral cortex and dopaminergic inputs from the substantia nigra (SN). Striatal dopamine loss decreases the number of MSN dendritic spines. This loss of spines has been suggested to reflect the removal of tonic dopamine inhibitory control over corticostriatal glutamatergic drive, with increased glutamate release culminating in MSN spine loss. We tested this hypothesis in two ways. We first determined in vivo if decortication reverses or prevents dopamine depletion-induced spine loss by placing motor cortex lesions 4 weeks after, or at the time of, 6-hydroxydopamine lesions of the SN. Animals were sacrificed 4 weeks after cortical lesions. Motor cortex lesions significantly reversed the loss of MSN spines elicited by dopamine denervation; a similar effect was observed in the prevention experiment. We then determined if modulating glutamate release in organotypic cocultures prevented spine loss. Treatment of the cultures with the mGluR2/3 agonist LY379268 to suppress corticostriatal glutamate release completely blocked spine loss in dopamine-denervated cultures. These studies provide the first evidence to show that MSN spine loss associated with parkinsonism can be reversed and point to suppression of corticostriatal glutamate release as a means of slowing progression in Parkinson's disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据